Aspirin with targeted therapy for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing whether adding aspirin to the targeted therapy combination of dabrafenib and trametinib is safe and works better for people with advanced lung cancer that has a specific BRAF gene change. It aims to make the existing treatment more effective and manageable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lung cancer is stage IIIB or IV and cannot be surgically removed.
- Your cancer has a certain genetic marker called BRAF V600E.
- You are planning to take the targeted therapy drugs dabrafenib and trametinib.
- You are able to care for yourself (performance status 0 or 1).
- Your main tumor is at least 1 centimeter (about the size of a pea) in diameter.
- You have not had other systemic cancer treatments for lung cancer before, but you may have taken aspirin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving targeted therapy before and after surgery helps people with a specific type of lung cancer (non-small cell lung cancer with a BRAF or MET mutation). The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of chemotherapy and a targeted drug (befotertinib) for people with non-small cell lung cancer whose cancer has stopped responding to a common type of targeted therapy. It aims to see if this new sequence can help overcome resistance.
This trial tests a newer type of EGFR targeted therapy pill for people with advanced non-small cell lung cancer who have not had prior treatment and whose cancer has a specific genetic change called a PACC mutation. The goal is to see if the drug works well for this group.
This trial tests two targeted drugs (dabrafenib and trametinib) for patients whose cancer has a specific change in the BRAF gene called V600. These drugs work together to block signals that help the cancer grow. The trial is for children, teenagers, and adults with many types of cancer, except for a few common ones that already have approved treatments.
This trial tests dabrafenib plus trametinib in people whose solid tumors have a BRAF V600E mutation that cannot be fully removed by surgery or has spread. It looks at whether these targeted medicines can shrink tumors and control the disease.
This Phase 2 trial tests a targeted treatment for adults with papillary craniopharyngioma that has a specific BRAF change (V600E). It may help shrink or control the tumor, especially when surgery is not expected to remove it safely.
Hear when a new BRAF V600E Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.